Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes

Br J Haematol. 2019 Feb;184(3):450-455. doi: 10.1111/bjh.15099. Epub 2018 Jan 23.
No abstract available

Keywords: EZH2; immunohistochemistry; mutation; myelodysplastic syndromes; survival.

Publication types

  • Letter

MeSH terms

  • Disease-Free Survival
  • Enhancer of Zeste Homolog 2 Protein* / biosynthesis
  • Enhancer of Zeste Homolog 2 Protein* / genetics
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Hematologic Neoplasms* / genetics
  • Hematologic Neoplasms* / metabolism
  • Hematologic Neoplasms* / mortality
  • Hematologic Neoplasms* / pathology
  • Humans
  • Immunohistochemistry
  • Male
  • Mutation*
  • Myelodysplastic Syndromes* / genetics
  • Myelodysplastic Syndromes* / metabolism
  • Myelodysplastic Syndromes* / mortality
  • Myelodysplastic Syndromes* / pathology
  • Neoplasm Proteins* / biosynthesis
  • Neoplasm Proteins* / genetics
  • Survival Rate

Substances

  • Neoplasm Proteins
  • EZH2 protein, human
  • Enhancer of Zeste Homolog 2 Protein